WO2005079748A3 - Preparation pharmaceutique pour la liberation prolongee d'un ingredient pharmaceutiquement actif - Google Patents

Preparation pharmaceutique pour la liberation prolongee d'un ingredient pharmaceutiquement actif Download PDF

Info

Publication number
WO2005079748A3
WO2005079748A3 PCT/EP2005/001154 EP2005001154W WO2005079748A3 WO 2005079748 A3 WO2005079748 A3 WO 2005079748A3 EP 2005001154 W EP2005001154 W EP 2005001154W WO 2005079748 A3 WO2005079748 A3 WO 2005079748A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
pharmaceutically active
sustained release
pharmaceutical preparation
weight
Prior art date
Application number
PCT/EP2005/001154
Other languages
English (en)
Other versions
WO2005079748A2 (fr
Inventor
Sanchez Francisco Jurado
Pablo Sedano Marta De
Campano Monica Argilaga
Original Assignee
Lacer Sa
Sanchez Francisco Jurado
Pablo Sedano Marta De
Campano Monica Argilaga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer Sa, Sanchez Francisco Jurado, Pablo Sedano Marta De, Campano Monica Argilaga filed Critical Lacer Sa
Publication of WO2005079748A2 publication Critical patent/WO2005079748A2/fr
Publication of WO2005079748A3 publication Critical patent/WO2005079748A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une préparation pharmaceutique destinée à la libération prolongée d'un ingrédient pharmaceutiquement actif. Cette préparation pharmaceutique qui libère de façon prolongée un ou plusieurs ingrédients pharmaceutiquement actifs contient des particules qui présentent un noyau intérieur (1) entouré d'une première pellicule (2), laquelle contient un mélange de: (a) entre 50 et 95 % en poids d'un copolymère d'acrylate d'éthyle, de méthylméthacrylate et de chlorure de méthacrylate triméthylamminoéthylique dans un rapport molaire de trois acrylates de 1: 1,8-2,2: 0,08-0,12, préférablement, 1:2:0,1, (b) entre 2 et 30 % en poids d'un copolymère d'éthylacrylate et d'acide méthacrylique dans un rapport molaire de 1: 0,8-1,2, préférablement de 1:1, et enfin, (c) entre 1 et 40 % en poids de l'ingrédient pharmaceutiquement actif.
PCT/EP2005/001154 2004-02-13 2005-02-04 Preparation pharmaceutique pour la liberation prolongee d'un ingredient pharmaceutiquement actif WO2005079748A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400338A ES2241478B1 (es) 2004-02-13 2004-02-13 Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
ESP200400338 2004-02-13

Publications (2)

Publication Number Publication Date
WO2005079748A2 WO2005079748A2 (fr) 2005-09-01
WO2005079748A3 true WO2005079748A3 (fr) 2006-06-08

Family

ID=34878429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001154 WO2005079748A2 (fr) 2004-02-13 2005-02-04 Preparation pharmaceutique pour la liberation prolongee d'un ingredient pharmaceutiquement actif

Country Status (2)

Country Link
ES (1) ES2241478B1 (fr)
WO (1) WO2005079748A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234353A1 (en) 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2007002518A1 (fr) * 2005-06-23 2007-01-04 Spherics, Inc. Formes de dosage de pramipexole a liberation retardee ou a liberation prolongee/retardee
EP1810668A1 (fr) * 2006-01-23 2007-07-25 LEK Pharmaceuticals D.D. Compositions pharmaceutiques enrobées à base de tartrate de toltérodine
JP2007308479A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (fr) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Formulations à libération prolongée de topiramate
WO2009019599A2 (fr) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Compositions à libération prolongée comprenant de la toltérodine
WO2010027603A2 (fr) * 2008-09-03 2010-03-11 Elc Management Llc Compositions comportant des particules solides encapsulées dans une matrice de silicone réticulé, et leurs procédés de fabrication
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
EP2829270B1 (fr) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Produit d'association contenant de la synéphrine et du topiramate
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN104337773B (zh) * 2013-08-06 2018-11-30 天士力医药集团股份有限公司 穿心莲内酯在制备炎症性肠病的药物中的应用、穿心莲内酯肠溶靶向微丸及其制备方法
DE102018129419A1 (de) * 2018-11-22 2020-05-28 Johannes Gutenberg-Universität Mainz Acrylat-Copolymer für galenische Anwendungen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720473B1 (fr) * 1993-09-23 1998-11-11 Dr. Falk Pharma Gmbh Pellets de budesonide a liberation controlee et leur procede de preparation
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AU6715600A (en) * 1999-08-26 2001-03-19 Elan Corporation, Plc Pharmaceutical formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720473B1 (fr) * 1993-09-23 1998-11-11 Dr. Falk Pharma Gmbh Pellets de budesonide a liberation controlee et leur procede de preparation
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKBUGA JULIDE: "Effect of microsphere size and formulaton factors on drug release from controlled-release furosemide microspheres", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 17, no. 4, 1991, pages 593 - 607, XP008062720 *
PONGPAIBUL Y, PRICE JC, WHITWORTH CW: "Preparation and evaluation of controlled release indomethacin microspheres", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 10, no. 10, 1984, pages 1597 - 1616, XP008062731 *
TSANKOV S, LAMBOV N; MINKOV E: "Regulation of tetracycline hydrochloride release from polyacrylate microspheres.", PHARMAZEUTISCHE INDUSTRIE, vol. 57, no. 12, 1995, pages 1044 - 1047, XP008062723 *

Also Published As

Publication number Publication date
WO2005079748A2 (fr) 2005-09-01
ES2241478A1 (es) 2005-10-16
ES2241478B1 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
WO2005079748A3 (fr) Preparation pharmaceutique pour la liberation prolongee d'un ingredient pharmaceutiquement actif
WO2005046649A3 (fr) Forme galenique multicouche contenant une substance a action modulatrice par rapport a la liberation du principe actif
WO2007006353A3 (fr) Utilisation d'un copolymere (meth)acrylique anionique partiellement neutralise comme enrobage dans la production d'une forme medicamenteuse liberant le principe actif a un ph reduit
WO2000019984A3 (fr) Formes medicamenteuses enrobees a liberation controlee du principe actif
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
EP2158905A3 (fr) Composition pour l'administration transdermique de Fentanyle
CA2370067A1 (fr) Forme posologique pharmaceutique de liberation controlee produisant au moins un pulse minute
WO2005070462A3 (fr) Compositions comprenant de la (s)-amlodipine et un bloqueur du recepteur de l'angiotensine, et leurs methodes d'utilisation
WO2004062577A3 (fr) Utilisation d'un melange de deux ou de plusieurs materiaux enteriques afin de reguler la liberation de medicaments via une membrane ou une matrice dans des therapies systemiques
IL151151A0 (en) Coating and binding agent for pharmaceutical formulations having improved storage stability
IL167334A (en) Multilayer dosage forms which contain active substances and which comprise a neutral core and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers
WO2005041968A3 (fr) Formes posologiques orales d'oxycodone en dose quotidienne unique et a liberation controlee
WO2007011619A3 (fr) Formes pharmaceutiques orales hautement biodisponibles a liberation retardee, de o-desmethylvenlafaxine succinate
CA2317106A1 (fr) Procede et composition d'une preparation orale d'itraconazole
WO2006010394A3 (fr) Médicament de forme multicouche
WO2004112756A8 (fr) Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2002069939A3 (fr) Compositions pharmaceutiques au gout dissimule
WO2008084698A1 (fr) Composition pharmaceutique à libération entretenue de tacrolimus
WO2005099666A3 (fr) Formulations de 6-mercaptopurine a liberation retardee
WO2006062933A3 (fr) Compositions stables de fenofibrate comprenant des esters d'acides gras
CA2470656A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine
DE59810803D1 (de) Kontrolliert freisetzende pharmazeutische zubereitung mit einem ace-hemmer als wirkstoff
NZ535750A (en) Film coating for controlled release of pharmaceutical drugs
WO2003105811A3 (fr) Compositions a liberation progressive et son procede d'utilisation
WO2003099203A3 (fr) Comprime de cafeine gastro-resistant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase